

The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, *Aequorea victoria*. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transcriptional capping method, which results in the naturally occurring Cap 1 structure with high capping efficiency. It is polyadenylated and optimized for mammalian systems. It mimics a fully processed mature mRNA.

L-7601-100 (100 µgrams¹)
L-7601-1000 (1 mg)
L-7601-BK (Bulk amount)

1.0 mg/mL in 1 mM Sodium Citrate, pH 6.4
mRNA Length: 996 nucleotides

Store at or below -40°C

QC Analysis

Identity and Purity
Agarose Gel Mobility; Pass
Concentration: ± 6%; Pass

Product released by Quality Assurance

¹A standard conversion factor of 40 µg/OD₂₆₀ was used to calculate quantity.

Handling

Store at or below -40°C. Thaw and work with mRNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. Do not vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. Do not mix with media containing serum unless first complexed with a stabilizing transfection reagent.

Products containing the CleanCap technology are for research use only. Not for use in diagnostic or therapeutic procedures. Use of CleanCap technology may be covered by one or more patents or pending Patent Applications. www.trilinkbiotech.com/cleancap/license.asp.

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

The Modified Nucleic Acid **Experts™**

IMPORTANT INSTRUCTIONS – READ CAREFULLY: Unless you are an entity of the United States government, this Label License Agreement (“Agreement”) is the legal agreement between you (hereinafter “Licensee”) and Life Technologies Corporation (“LTC”) (individually, a “Party” or together, the “Parties”), for the use of products containing fluorescent proteins and/or genes covered by patents owned or controlled by LTC (“Products”), which Products are provided to you by LTC’s sub-licensee TriLink BioTechnologies Inc.

1. Use of Products by Licensee. LTC grants to Licensee a non-exclusive, non-transferable right to use only the purchased amount of this Product solely for Licensee’s activities directed to internal use by Licensee solely in applications of Licensee in scientific research.

Title to nucleic acids encoding fluorescent proteins covered by any of the patents listed below shall not transfer to the Licensee. LTC retains all rights not expressly granted herein, and there are no implied licenses granted herein. The Products may be covered by one or more U.S. or ex-U.S. patents. If your entity is a for-profit entity, or a not-for profit entity that is majority-owned by a for-profit entity, you warrant that you have already obtained a GFP license for the Research Field from LTC and/or GE Healthcare.

2. Excluded Uses. No permission is granted hereunder for Licensee to use the Products in any field(s) other than as designated under Section 1 of this Agreement. Specifically, no permission is granted hereunder for Licensee to use the Products for the purposes of: (i) providing services to third parties; (ii) transferring, selling, disclosing, or otherwise providing access to this Product, or any product, process, method, composition of matter and/or biological material derived therefrom, to any third party (iii) applications which require regulatory approval, including any in vitro diagnostic or therapeutic applications in humans or any in vivo use in humans for any purpose; (iv) prophylactics; (v) agrochemistry, veterinary applications, and/or consumer product applications (such as flavors, fragrances, and taste enhancers), and/or (vi) use in or with plants (including plant cells). The patents assigned to Stanford University may not be practiced in the field of anti-infectives. Licensee acknowledges that Licensee shall not have the right to authorize any third party to use or sell any Products or derivatives of the Products which contain fluorescent proteins/genes covered by patents owned or controlled by LTC.

3. Misuse of the Products and Indemnification Terms. To the extent provided by law, Licensee will defend, indemnify and hold harmless LTC, LTC’s affiliates, the Regents of the University of California and Howard Hughes Medical Institute, their managers, directors, officers, employees, sponsors, and agents (collectively the “Indemnified Parties”) against any and all liability, loss, damage, claim or expense, including attorney’s fees, (collectively the “Indemnified Losses”) arising out of or in connection with this Agreement, including, without limitation Indemnified Losses resulting from any use by the Licensee, Licensee’s employees or students of the Products and any products derived therefrom. Licensee will indemnify and hold harmless the Indemnified Parties against any and all Indemnified Losses resulting from, arising out of or relating to: (i) product liability claims of any nature; (ii) claims arising from Licensee’s failure to comply with all governmental regulations relating in any way to use or storage of the Products; (iii) Licensee’s breach of this Agreement; and (iv) claims by a third party that Licensee, Licensee’s employees or students use of the Products infringes or violates any patent copyright, trademark or property rights of such third party. This agreement shall be interpreted and enforced in accordance with the laws of the State of California in the United States.

Licensee agree to indemnify, hold harmless and defend Stanford University and the related Stanford hospitals and clinics and their respective trustees, officers, employees, students and agents against any and all claims for death, illness, personal injury, property damage and improper business practices arising out of the manufacture, use, sale, or other disposition of Stanford Patents or Stanford Licensed Products by Licensee. “Stanford Licensed Product” means any product or process, or part thereof, in the permitted field of use, the manufacture, use or sale of which is covered by a valid claim of an issued, unexpired Stanford Patent and shall be presumed to be valid unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken; and “Stanford Patent” means those of the patents referred to in Clause 1 above that are owned by Stanford.

4. DISCLAIMER OF WARRANTY. NEITHER LTC NOR ANY OF ITS AFFILIATES MAKES ANY WARRANTY, EXPRESS, OR IMPLIED WITH RESPECT TO THE PRODUCTS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR THAT THE PRODUCTS DO NOT INFRINGE ANY PATENT.

Except as expressly set forth in this Agreement, Stanford MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE STANFORD LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

5. Term. This Agreement shall commence upon the receipt of the Products and, subject to Section 7, continue as long as the Products are in the possession of the Licensee.

6. Termination. Either Party may terminate this Agreement for any reason upon thirty (30) days’ written notice to the other Party. The rights and obligations under Sections 3, 4, 6, and 7 shall survive any termination, expiration, or completion of this Agreement with respect to information generated and activities and events occurring prior thereto. Upon expiration or any termination of this Agreement, Licensee shall promptly destroy all remaining Products and, if permitted, all Products cloned, replicated or otherwise reproduced.

7. Entire Agreement and Assignability. This Agreement sets forth the complete and entire agreement of the Parties with respect to Products and supersedes and terminates all prior agreements and understandings between the Parties. No subsequent amendment or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. This Agreement shall not be assigned or otherwise transferred by Licensee.

Title	Publication/ Patent Number	Serial Number	Filing Date	Country
FACS-Optimized Green Fluorescent Protein Mutants with Different Excitation Wavelengths	Expired	60/008,232	6-Dec-95	United States
FACS-Optimized Green Fluorescent Protein Mutants with Different Excitation Wavelengths	5,968,738	08/761,771	6-Dec-96	United States
FACS-Optimized Mutants of the Green Fluorescent Protein (GFP)	Expired	60/010,960	1-Feb-96	United States
FACS-Optimized Mutants of the Green Fluorescent Protein (GFP)	5,804,387	08/791,332	31-Jan-97	United States
Fluorescence-Based Isolation of Differentially Induced Genes	5,994,077	08/926,556	10-Sep-97	United States
FACS-Optimized Mutants of the Green Fluorescent Protein (GFP)	6,090,919	09/135,418	17-Aug-98	United States
Modified Green Fluorescent Proteins	5,625,048	08/337,915	10-Nov-94	United States
Modified Green Fluorescent Proteins	6,319,669	08/727,452	20-Mar-97	United States
Modified Green Fluorescent Proteins	6,066,476	08/753,144	20-Nov-96	United States
Modified Green Fluorescent Proteins	5,777,079	08/753,143	20-Nov-96	United States
Modified Green Fluorescent Proteins	6,800,733	10/024,686	17-Dec-01	United States
Modified Green Fluorescent Proteins	3283523	08-520626	13-Nov-95	Japan
Modified Green Fluorescent Proteins	702205	41550/96	13-Nov-95	Australia
Modified Green Fluorescent Proteins	2,205,006	2,205,006	13-Nov-95	Canada
Modified Green Fluorescent Proteins	2,343,586	2,343,586	13-Nov-95	Canada
Modified Green Fluorescent Proteins	804457	95939898.3	13-Nov-95	Europe - including corresponding patents in AT, BE, CH, DE, DK, ES, FR, GR, IE, IT, LI, LU, MC, NL, PT, SE, GB
Modified Green Fluorescent Proteins	1104769 (pending)	1105011.9	13-Nov-95	Europe
Modified Green Fluorescent Proteins	295 22 103 (Utility Model)	9522103	13-Nov-95	Germany
Long Wavelength Engineered Fluorescent Proteins	6,124,128	08/706,408	30-Aug-96	United States
Long Wavelength Engineered Fluorescent Proteins	6,054,321	08/911,825	15-Aug-97	United States
Long Wavelength Engineered Fluorescent Proteins	6,077,707	08/974,737	19-Nov-97	United States
Long Wavelength Engineered Fluorescent Proteins	6,403,374	09/465,142	16-Dec-99	United States
Long Wavelength Engineered Fluorescent Proteins	6,593,135	09/575,847	19-May-00	United States
Long Wavelength Engineered Fluorescent Proteins	6,780,975	10/071,976	5-Feb-02	United States
Long Wavelength Engineered Fluorescent Proteins	7,544,776	10/620,099	14-Jul-03	United States
Long Wavelength Engineered Fluorescent Proteins	7,560,287	10/924,232	23-Aug-04	United States
Long Wavelength Engineered Fluorescent Proteins	pending	13/011,432	21-Jan-11	United States
Long Wavelength Engineered Fluorescent Proteins	4322992	10-510109	15-Aug-97	Japan
Long Wavelength Engineered Fluorescent Proteins	4427222	2001-586334	17-May-01	Japan
Long Wavelength Engineered Fluorescent Proteins	727088	43277/97	15-Aug-97	Australia
Long Wavelength Engineered Fluorescent Proteins	767375	23196/01	15-Aug-97	Australia
Long Wavelength Engineered Fluorescent Proteins	2,232,242	2,232,242	15-Aug-97	Canada
Long Wavelength Engineered Fluorescent Proteins	2408302 (pending)	2,408,302	17-May-01	Canada
Long Wavelength Engineered Fluorescent Proteins	886644	97941350.7	15-Aug-97	Europe - including corresponding patents in CH, DE, DK, ES, FR, IE, IT, LI, NL, SE, GB
Long Wavelength Engineered Fluorescent Proteins	1285065	20010937550	17-May-01	Europe - including corresponding patents in CH, DE, DK, ES, FR, IE, IT, LI, NL, SE, GB
Long Wavelength Engineered Fluorescent Proteins	Granted	982972	15-Aug-97	Mexico
Fluorescent Proteins	6,919,186	09/967,301	28-Sep-01	United States
Fluorescent Proteins	7,091,317	10/757,624	14-Jan-04	United States
Fluorescent Proteins and methods of using same	7,300,762	11/251,209	14-Oct-05	United States
Mutants of Green Fluorescent Protein	EP1381625	EP01972260.2	28-Sep-01	Europe (BE, CH, DE, ES, FR, IT, LI, NL, SE)
Mutants of Green Fluorescent Protein	2,445,035	2,445,035	28-Sep-01	Canada
Mutants of Green Fluorescent Protein	2001292040	2001292040	28-Sep-01	Australia
Mutants of Green Fluorescent Protein	WO 02/085936	PCT/01GB/04363	28-Sep-01	PCT
Novel Fluorescent Proteins	6,172,188	08/819,612	31-Jan-96	United States
Novel Fluorescent Proteins	6,818,443	09/872,364	1-Jun-01	United States
Novel Fluorescent Proteins	7,314,915	10/947,178	23-Sep-04	United States
Novel Variants of Green Fluorescent Protein, GFP	2,232,727	2,232,727	31-Jan-96	Canada
Novel Variants of Green Fluorescent Protein, GFP	EP0851874	96900890.3	31-Jan-96	Europe (BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, SE)
Novel Variants of Green Fluorescent Protein, GFP	WO 97/11094	PCT/1996DK/00051	31-Jan-96	PCT
Novel Fluorescent Proteins	7,001,986	09/887,784	19-Jun-01	United States
Nucleic Acids Encoding Fluorescent Proteins and Methods of Using the Same	7,476,518	11/206,904	19-Aug-05	United States
Fluorescent Proteins	2001279669	2001279669	18-Jun-01	Australia
Fluorescent Proteins	2,410,413	2,410,413	18-Jun-01	Canada
Fluorescent Proteins	EP1299414	1957861.6	18-Jun-01	Europe (BE, CH, CY, DE, DK, ES, FR, GB, IE, IT, LI, LU, MC, NL, SE, TR)
Novel Fluorescent Proteins	4459944	2006-304095	9-Nov-06	Japan
Novel Fluorescent Proteins	WO 01/98338	PCT/2001EP/06848	18-Jun-01	PCT